/
Immunology
Granulomatosis With Polyangiitis
11
Pipeline Programs↗
13
Active Trials↗
10
Companies Involved↗
Granulomatosis with Polyangiitis is an emerging landscape with 11 programs across 10 companies. The most active players are Guangdong Hengrui Pharmaceutical Co., Ltd, NS Pharma. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 37
Approved
No programs
Analysis
Modality Breakdown
64%
Monoclonal antibody
7 of 11 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
27
clinical trials
Completed11 · 41%
Recruiting7 · 26%
Active, not recruiting3 · 11%
Not yet recruiting2 · 7%
Unknown status2 · 7%
Enrolling by invitation1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
27 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)